Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma
Overview
This study highlights the role of CD38 enzymatic activity in multiple myeloma and its implications for antibody-driven therapies. It demonstrates that while CD38-targeting monoclonal antibodies like daratumumab and isatuximab promote NAD+ degradation, adenosinergic metabolism remains active, potentially contributing to immune evasion and resistance.
Background
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of malignant plasma cells in an immunosuppressive bone marrow environment. CD38, a multifunctional ectoenzyme, plays a crucial role in this process by degrading NAD+ and contributing to adenosine production, which promotes immune suppression. Understanding CD38's enzymatic functions is essential for improving therapeutic strategies and overcoming resistance to current treatments.
Data Highlights
The study found that both daratumumab and isatuximab promoted NAD+ degradation in vitro, leading to increased ADPR levels. In vivo, adenosine concentrations in bone marrow plasma remained elevated during treatment, while inosine levels increased, indicating ongoing adenosinergic metabolism.
Key Findings
CD38-targeting mAbs induce NAD+ degradation and ADPR accumulation in MM cells.
Adenosine concentrations in the bone marrow remain elevated during daratumumab therapy.
Inosine levels progressively increase during treatment, affecting the bone marrow-peripheral blood gradient.
Persistent adenosinergic immunosuppression may contribute to therapeutic resistance in MM.
Combining CD38-directed antibodies with agents targeting adenosinergic signaling may enhance treatment efficacy.
Clinical Implications
Clinicians should consider the persistent immunosuppressive effects of adenosine during CD38-targeted therapies. Combining these therapies with agents that inhibit adenosinergic signaling may improve patient outcomes and reduce resistance.
Conclusion
The findings underscore the importance of understanding CD38's enzymatic role in multiple myeloma treatment and suggest that targeting adenosinergic pathways may enhance the effectiveness of current therapies.
